TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04978571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous electrical nerve-field stimulation, PENFS
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: percutaneous electrical nerve-field stimulation, PENFS (sham device)
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
Description: A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
Study: NCT05387837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Study: NCT06079918

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Micronutrient Supplements with 30 mg of elemental iron
Description: MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements with 45 mg of elemental iron
Description: MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements with 60 mg of elemental iron
Description: MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
Study: NCT05691920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectointercostal plane block and external oblique intercostal plane block
Description: Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
Study: NCT05387837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-4517.2
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Study: NCT05179837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography probe
Description: The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
Study: NCT05404893

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin measurement
Description: Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin measurement
Description: Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin measurement
Description: Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
Study: NCT05824442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample for multiplex QPCR technique
Description: Blood sampling specifically for qPCR Echino at inclusion and one year after
Study: NCT06530264

Intervention type: OTHER
Group type: OTHER
Intervention: DCR
Description: 6. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
Study: NCT06326437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week dyadic intervention
Description: Comprising 1 session with 60-90min, followed by 5 weekly internet-based sessions.
Study: NCT06554548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10518
Description: Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10518
Description: Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
Study: NCT05214287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxic Gas Mixture
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
Study: NCT06017167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .
Description: compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4mg + dexamethasone 8mg + normal saline.
Description: Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
Study: NCT05790616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial blood draw
Description: For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values.
Study: NCT03680976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
Study: NCT04703517

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ultrasound
Description: Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
Study: NCT06580327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: programmed intermittent Bolus epidural analgesia
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT05790616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen reduction
Description: Volunteers undergo an ambient oxygen decrease from 21% to 10%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen reduction
Description: Volunteers undergo an ambient oxygen decrease from 21% to 10%
Study: NCT06580327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT05790616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen reduction
Description: Volunteers undergo an ambient oxygen decrease from 21% to 10%
Study: NCT06608940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402
Description: BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
Study: NCT06452329

Intervention type: DRUG
Intervention: Nivolumab
Description: As prescribed by treating physician
Study: NCT06616285

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-Guided Multidomain Lifestyle Intervention
Description: Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Folk Dance Multidomain Lifestyle Intervention
Description: Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
Study: NCT06617039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and ciprofol
Description: R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine 0.3mg/kg and ciprofol
Description: Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine 0.5mg/kg and ciprofol
Description: Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofol
Description: Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
Study: NCT06617377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan
Description: advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
Study: NCT06680817

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.
Study: NCT06616974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TX000045- Dose A
Description: The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TX000045- Dose B
Description: The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
Study: NCT06616116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosignal feedback
Description: 1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
Study: NCT04751474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational messages
Description: Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
Study: NCT06083636

Intervention type: OTHER
Intervention: Single extra blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.

Intervention type: OTHER
Intervention: Single extra blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.

Intervention type: OTHER
Intervention: Single extra blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Study: NCT05081310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: superior vena cava isolation
Description: SVC isolation by the means of cryoballoon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation
Description: conventional pulmonary vein isolation by the means of cryoballoon
Study: NCT06083636

Intervention type: OTHER
Intervention: Single extra blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.

Intervention type: OTHER
Intervention: Single blood draw and completion of single questionnaire
Description: Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
Study: NCT05629871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Polysomnography will be performed for 24 hours at inclusion and 24 months
Study: NCT05005065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 X mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 X mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001 Y mg
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001 Y mg
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Y mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Y mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Z mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 Z mg
Description: Oral capsule
Study: NCT05629871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A full neuropsychological assessment will be performed at inclusion, 12 and 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on sleep and behavioural problems
Description: Questionnaires on sleep and behavioural problems

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: Measurement of actimetrics for 14 days at inclusion and at 24 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractional diuresis
Description: Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal temperature measurement
Description: eCelsius capsule to measure internal temperature at inclusion and 24 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker assay
Description: Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
Study: NCT03271515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 anti-CD20 Bispecific CAR-T
Description: patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
Study: NCT05934526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seralutinib
Description: Capsule containing seralutinib

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for seralutinib or placebo delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for seralutinib or placebo delivery
Study: NCT06660355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a Janus kinase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is a glucocorticoid.
Study: NCT06661304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Exercise
Description: Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
Study: NCT05197855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deem 3 Headband
Description: The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
Study: NCT05687344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine ER
Description: Postpartum BP treatment to \<140/90 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine ER
Description: Postpartum BP treatment to \<140/90 mmHg
Study: NCT05852327

Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study: NCT06544161

Intervention type: DEVICE
Group type: OTHER
Intervention: CPMX2
Description: The CPMX2 is a point-of-care device for non-invasive, real-time, and intermittent monitoring of vascular occlusion pressure.